As of September 30, 2025, the Company had cash of approximately $9.9 million. While trial costs are difficult to estimate and the Company does not yet have firm estimates as the trial design for the upcoming trial of TPI 287 is not yet fixed, the Company believes that it has sufficient working capital to fund operations into the second half of 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off